GIBSON DUNN

Gibson Dunn Advises BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics

Firm News | January 23, 2026

Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility, to finance, in part, the acquisition of Astria Therapeutics, Inc.

Gibson Dunn regularly advises life sciences companies on complex financing transactions supporting strategic acquisitions.

The Gibson Dunn finance team involved in the transaction was led by Jin Hee Kim and included Paul Rafla, Jaclyn Wang, Aliya Zuberi, and Ruoqi Wei. Karen Spindler and Meghan Hungate advised on certain licensing and intellectual property matters. Michael Dziuban and Carlo Felizardo advised on certain FDA and regulatory matters. Matt Donnelly, Kate Long, and Jason Zhang advised on certain tax matters.

Related People

Jin Hee Kim

Paul Rafla

Jaclyn Wang

Aliya Zuberi

Ruoqi Wei

Karen A. Spindler

Meghan M. Hungate

Michael R. Dziuban

Kate Long

Jason Zhang

Related Capabilities

Finance

Life Sciences

Intellectual Property

Technology Transactions

FDA and Health Care

Tax

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**